[1]
Boér K. Fulvestrant in advanced breast cancer: evidence to date and place in therapy. Therapeutic advances in medical oncology. 2017 Jul:9(7):465-479. doi: 10.1177/1758834017711097. Epub 2017 Jun 19
[PubMed PMID: 28717399]
Level 3 (low-level) evidence
[2]
Lee CI, Goodwin A, Wilcken N. Fulvestrant for hormone-sensitive metastatic breast cancer. The Cochrane database of systematic reviews. 2017 Jan 3:1(1):CD011093. doi: 10.1002/14651858.CD011093.pub2. Epub 2017 Jan 3
[PubMed PMID: 28043088]
Level 1 (high-level) evidence
[3]
Markham A. Alpelisib: First Global Approval. Drugs. 2019 Jul:79(11):1249-1253. doi: 10.1007/s40265-019-01161-6. Epub
[PubMed PMID: 31256368]
[4]
Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Sondhi M, Wang Y, Chakravartty A, Rodriguez-Lorenc K, Taran T, Jerusalem G. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. The New England journal of medicine. 2020 Feb 6:382(6):514-524. doi: 10.1056/NEJMoa1911149. Epub 2019 Dec 11
[PubMed PMID: 31826360]
[5]
Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M, PALOMA3 Study Group. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. The New England journal of medicine. 2015 Jul 16:373(3):209-19. doi: 10.1056/NEJMoa1505270. Epub 2015 Jun 1
[PubMed PMID: 26030518]
[6]
Nathan MR, Schmid P. A Review of Fulvestrant in Breast Cancer. Oncology and therapy. 2017:5(1):17-29. doi: 10.1007/s40487-017-0046-2. Epub 2017 May 8
[PubMed PMID: 28680952]
[7]
Croxtall JD, McKeage K. Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women. Drugs. 2011 Feb 12:71(3):363-80. doi: 10.2165/11204810-000000000-00000. Epub
[PubMed PMID: 21319872]
[8]
Bross PF, Cohen MH, Williams GA, Pazdur R. FDA drug approval summaries: fulvestrant. The oncologist. 2002:7(6):477-80
[PubMed PMID: 12490735]
[9]
Morales-Conde M, López-Ibáñez N, Calvete-Candenas J, Mendonça FMI. Fulvestrant-induced toxic epidermal necrolysis. Anais brasileiros de dermatologia. 2019 Mar-Apr:94(2):218-220. doi: 10.1590/abd1806-4841.20197964. Epub 2019 May 9
[PubMed PMID: 31090829]
[10]
Vergote I, Robertson JF. Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials. British journal of cancer. 2004 Mar:90 Suppl 1(Suppl 1):S11-4
[PubMed PMID: 15094759]
[11]
Hawle H, Hess D, Mueller A, Thuerlimann B. Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer. Case reports in oncology. 2010 Apr 29:3(2):131-136
[PubMed PMID: 20740185]
Level 3 (low-level) evidence
[12]
Cheung KL, Robertson JF. Fulvestrant. Expert opinion on investigational drugs. 2002 Feb:11(2):303-8
[PubMed PMID: 11829719]
Level 3 (low-level) evidence
[13]
Robertson JF, Harrison M. Fulvestrant: pharmacokinetics and pharmacology. British journal of cancer. 2004 Mar:90 Suppl 1(Suppl 1):S7-10
[PubMed PMID: 15094758]
[14]
Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Robertson JF, Brufsky A, Possinger K, Rennie P, Sapunar F, Lowe E, Piccart M. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Apr 1:26(10):1664-70. doi: 10.1200/JCO.2007.13.5822. Epub 2008 Mar 3
[PubMed PMID: 18316794]
Level 1 (high-level) evidence